drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy (CAR T cells)
drug_description
Gene-modified autologous T cells engineered to express a CD19-directed chimeric antigen receptor, leading to T-cell activation and cytotoxic killing of CD19-positive B-cell lymphoma.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene-modified ex vivo to express a CD19-directed chimeric antigen receptor. Upon binding CD19 on B cells, the CAR transmits activation signals (CD3ΞΆ with costimulatory domains), driving T-cell expansion, cytokine release, and perforin/granzyme-mediated cytotoxic killing of CD19-positive malignant B cells.
drug_name
Autologous anti-CD19 CAR T-cell therapy
nct_id_drug_ref
NCT06567366